| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3694 |
| Trial ID | NCT06179524 |
| Disease | B-Cell Acute Lymphoblastic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Phase II Clinical Study of CAR-T-19 (Anti-CD19 Single-chain Antibody Chimeric Antigen Receptor T Cell) Injection in the Treatment of CD19-positive Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia(B-ALL) Under 25 Years of Age (Inclusive) |
| Year | 2023 |
| Country | China |
| Company sponsor | Beijing Yongtai Ruike Biotechnology Company Ltd |
| Other ID(s) | CT19-ALL-02 |
| Cohort 1 | |||||||||||||
|
|||||||||||||